The effectiveness of olmesartan on inflammation at cardiopulmonary bypass

Aim: Systemic inflammatory response syndrome may develop after coronary artery bypass graft surgery that performed by cardiopulmonary bypass technique. It is known that olmesartan, an angiotensin II receptor blocker, has anti-inflammatory effects. The antiinflammatory efficacy of olmesartan treatment was investigated in patients undergoing cardiopulmonary bypass.Materials and Methods: The study included 50 patients (14 female, 36 male) between 30-80 years of age were underwent CABG surgery. Patients were randomly assigned to control (Group C) and olmesartan (Group O) gruoups. Group O were treated with a single dose of 10 mg per day; 5 days preoperatively and 35 days postoperatively, 30 mg at the operation day. Samples were taken before the induction of anesthesia (T1), 5 minutes before cross clamping (T2), 5 minutes after cross clamping (T3), after protamine infusion (T4), postoperative day 3 (T5) and postoperative day 35 (T6) for total serum levels of IL-6, IL-10 and IL-18; for h-CRP levels preoperative (T1) and postoperative day 35 (T2).Results: Statistically significant decrease of CRP levels were observed on the postoperative 35th day in Group O (p

PDF

___

1. Schwartz D, Taberdel Y, Presier JC, et al. Does aprotinin influence the inflammatory response to cardiopulmaonary bypass in patients? J Thorac Cardiovasc Surg 2003;125:184-90.
2. Laffey JG, Boylan JF, Cheng DHC. The systemic inflammatory response to cardiac surgery. Anesthesiology 2002;199:215-52.
3. Paperalla D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiolgy and treatment. An update. Eur J Cardiothorac Surg 2002;21:232-44.
4. Hornick P, Taylor KM. Immune and inflammatory responses after cardiopulmonary bypass. In: Gravlee GP, Davis RF, Kurusz M, et al. Eds. Cardiopulmonary bypss: practice and principles, 2nd ed. Philadelphia: Lippincott Williams & Wilkins 2000:303-10.
5. Brix-Christensen V. The systemic Inflammatory response after cardiac surgery with cardiopulmonary bypass in children. Acta Anaesthesiol Scand 2001;45:671-9.
6. El Azab SR, Roseel PM, de Lange JJ, et al. Dexamethasone decreases the pro-to antiinflammatory cytokine ratio during cardiac surgery. Br J Anaesth 2002;88:496-501.
7. Giomarelli P, Scolletta S, Borelli E, et al. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg 2003;76:117-23.
8. Proudfoot JM, Croft KD, Puddey IB, et al. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 2003;305:846-53.
9. Sherwood ER, Toliver-Kinsky T. Mechenisms of inflammatory response. Best Practice Research Clinical Anesthesiolgy 2004;18:385-405.
10. Kirshfink M. Controlling the complement system in inflammation. Immunopharmacology 1997;38:51-62.
11. Wan S, Yim AP. Cytokines in myocardial injury: impact on cardiac surgical approach. Eur J Cardiothorac Surg 1999;16:107-11.
12. Oppenheim JJ and Saklatvala J. Clinical Applications of Cytokines. (ed J.J. Oppenheim J, Rossio L and Geraing J.H.) Oxford UniversityPres, Newyork 1993: 3-15.
13. Teranishi T, Hirano T, Arima N, et al. Human helper T cell factor(s) (ThF), II: induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor- (TRF) like factor(s). J Immunol 1982;128:1903-8.
14. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311-20.
15. Fickenser H, Hor S, Kupers H, et al. The IL-10 family of cytokines. Trends Immunol 2002;23:89-96.
16. Andrew Dp, Chang MS, McNinch J. CC Chemokine Acts Specifically on Chronically Activated Th2 Lymphocytes and is Produced by monocytes on Stimulation with Th2 Cytokines IL-4 and IL-13. Immunol 1998;161: 5027-38.
17. Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997;386:619-23.
18. Tone M, Thompson SA, Tone Y, et al. Regulation of IL- 18 (IFN-gamma-inducing factor) gene expression. J Immunol 1997;159:6156-63.
19. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C reactive protein for the targeting of statin theraphy in the primary prevention of acute coronary events. N. Eng J Med 2001;344:1959-65.
20. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinojen, homocysteine, lipoprotein(a), and Standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
21. Lin TC, Li CY, Tsai CS, et al. Neutrophilmediated secresyon and activasyon of matrixmetalloproteinase-9 during cardiac syrgery with cardiopulmonary bypass. surgery with cardiopulmonary bypass. Anesth Analg 2005;100:1554-60.
22. Franke A, Lante W, Fackeldy V, et al. Proinflammatory cytokines after cardiac operation: Different cellular soures at different times. Ann Thorac Surg 2002;74:363-71.
23. Mizuno M, Sada T, Kato M. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995;285:181-8.
24. Sarıbülbül O. Açık kalp makinası ve ekstrakorporeal dolaşım. Duran E editör. Kalp ve Damar Cerrahisi. İstanbul: Çapa Tıp Kitabevi 2004;75:1047-74.
25. Heidemann J, Ogawa H, Dwinell MB, et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 2003;278:8508-15.
26. Shames RS, Kishiyama JL. Bağışıklık sistemi hastalıkları. (Çevir: Avcı AB). Hastalıkların Patofizyolojisi (Ed: McPee S. çeviri Ed: Çoban E, Süleymanlar G.), 4. baskı 2006:31-57.
27. H.Argania, A.Ghorbanihaghjob, M.Aghaeishahsavarib, et al. Effects of Losartan and Enalapril on High- Sensitivity C-Reactive Protein and Total Antioxidant in Renal Transplant Recipients With Renin-Angiotensin System Polymorphisms. Transplantation Proceedings 2008;40:16-21.
28. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-7.
29. Heinzel FP, Hujer AM, Ahmed FN, et al. In vivo production and function of IL-12 p40 homodimers. J Immunol 1997;158:4381-8.
30. Ozguler IM, Burma O, Uysal A, et al. Rosuvastatin lowers systemic inflammatory response in coronary artery bypass graft accompanied by cardiopulmonary bypass surgery: A randomised controlled study. Clin Invest Med 2015;38:154-63.